Article Text

other Versions

PDF
Superior vena cava stenting in the 21st century
  1. Parveen Warner,
  2. Raman Uberoi
  1. Department of Radiology, John Radcliffe Hospital, Oxford, UK
  1. Correspondence to Dr Raman Uberoi, Department of Radiology, John Radcliffe Hospital, Headley way, Headington, Oxford OX3 9DU, UK; raman.uberoi{at}ouh.nhs.uk

Abstract

Superior vena cava obstruction (SVCO) is most commonly due to malignant or thrombotic causes. The traditional treatments of surgery, radiotherapy or chemotherapy either have a high morbidity and mortality rate, or a lag period of a few weeks prior to response. Superior vena cava stenting is able to provide rapid relief of symptoms safely in the vast majority of patients. It has now become the first-line treatment for malignant SVCO, and is increasingly being used in benign SVCO. The complication and success rates compare very favourably with the other treatment modalities.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.